WO2010085975A1 - Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs - Google Patents
Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs Download PDFInfo
- Publication number
- WO2010085975A1 WO2010085975A1 PCT/EP2009/000566 EP2009000566W WO2010085975A1 WO 2010085975 A1 WO2010085975 A1 WO 2010085975A1 EP 2009000566 W EP2009000566 W EP 2009000566W WO 2010085975 A1 WO2010085975 A1 WO 2010085975A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lipase
- pharmaceutical preparation
- bacterial
- treatment
- liquid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
Definitions
- the invention relates to pharmaceutical preparations for the treatment of pancreatic insufficiency, for example cystic fibrosis or other pancreatic disorders.
- the present invention relates to liquid pharmaceutical preparations of digestive enzymes which have no coating and are active in the aggressive environment of stomach / duodenum.
- these liquid pharmaceutical preparations are stable and can be stored at high temperatures.
- lipase enzymes mostly products based on porcine pancreas, which has been degreased, dried and crushed.
- the resulting product consists of several enzymes, such as lipase, amylases, proteases, esterases etc.
- Commonly available forms of administration are usually enteric coated tablets, microtablets, microdigars, capsules, powders and granules.
- enteric coated tablets, microtablets, microdigars, capsules, powders and granules are usually enteric coated tablets, microtablets, microdigars, capsules, powders and granules.
- the disadvantage of these modes of administration is the inconvenience of administering to the patient who has to swallow large tablets or capsules. Especially in the case of patients who are unable to swallow tablets, such as small children, or need artificial nutrition, these forms of administration are difficult to apply.
- the crushing of the tablets can not ensure a homogeneous distribution of the enzymes in the chyme and the low solubility of the
- the lipase is considered the lead enzyme. Due to the low specific lipase activity, an amount of up to 5-1O g per day has to be taken by the patients. In addition, the porcine lipase is active in a pH range of 5 to 9 and is therefore inactive during the passage of the stomach.
- the lipase activity must be protected from the acidic pH conditions in the stomach, for example by enteric coating of the tablets.
- the accompanying proteomics lytic or amylolytic enzyme activities are undesirable: amylase content is undesirable in cystic fibrosis-na ⁇ ve children, whereas lipases are therapeutically required.
- Proteases are contraindicated in patients with acute pancreatitis or active phases of chronic pancreatitis (see US 5,645,832). Therefore, the availability of a lipase as a single protein is advantageous.
- US Pat. No. 5,645,832 or US Pat. No. 5,489,530 a bacterial lipase has already been described in detail.
- the lipase concentration of bacterial lipase is very high so that only small amounts of substance (about 0.2 g) must be administered.
- the pH range for the activity of bacterial lipases is between 3 and 9 and therefore overcomes the limitations of stability and activity of porcine lipase / pancreatin. This means that the lipolytic action of the bacterial lipases can be used with greater effect in the gastrointestinal tract than the products marketed for the treatment of maldigestion on the market.
- the bacterial lipase is a non-animal product that avoids the risk of possible animal source virus contamination.
- the present invention provides a liquid pharmaceutical preparation containing a digestive enzyme.
- the product is used to treat patients with pancreatic insufficiency, for example cystic fibrosis or other pancreatic diseases.
- lipase without coating is active in the aggressive environment of stomach / duodenum and that the enzyme is stable in aqueous solution for several months at room temperature.
- bacterial lipase is able to reduce fat diarrhea in cystic fibrosis patients.
- the invention is based on a lipase produced in bacteria, and its preparation is expressly described in US 5,645,832.
- Lipase use has been shown to be effective in treating patients suffering from pancreatitis or cystic fibrosis.
- the reduction of fat diarrhea was observed with the exclusive use of lipase.
- No other enzymes such as proteases, amylases or esterases were present (Example 1).
- Pure bacterial lipase may have specific activities greater than 3.5 billion U / g. Because of this high lipolytic activity, patients must be given a lower amount of administration (i.e., number of tablets or volume of solution).
- the present invention offers the lipase as a liquid pharmaceutical preparation to overcome the limitations of the current formulations (tablets) of therapeutic digestive enzymes. Especially in the case of patients who are unable to swallow tablets, such as small children, or those who need artificial nutrition, the current administration forms are not or only partially applicable.
- a liquid pharmaceutical product offers the possibility of convenient dosage of the drug, homogeneous distribution of the enzyme in the diet and application in artificial nutrition.
- lipase is active without coating under pH conditions that mimic the aggressive environment of the stomach when ingested (Example 2). It has also been shown that the bacterial lipase in aqueous solution for at least 3 months even at high Temperatures is stable (Example 3). No chemical modification as described in US 2006/0128587 was required.
- compositions which also use stabilizers such as sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite
- the liquid formulation may be solutions, solution / drops; suspensions; Suspension drops.
- the invention is based on the advantages of liquid administration forms especially, but not exclusively, for children.
- Liquid dosage forms may be prepared either by preparing the lipase directly as a liquid solution or by dissolving the active ingredient in an aqueous or non-aqueous solvent, suspending the drug in a suitable environment, or by incorporating the drug in one of two phases of an oil / water system.
- Forms of administration such as solutions, suspensions and emulsions of lipase are useful for a number of reasons. They can be formulated for various routes of administration: oral ingestion, introduction into body cavities or external application. The dose may be adjusted by dilution and individual drops may be administered, for example, with a dropper.
- the liquid oral form can be readily administered to children or to humans who are unable to swallow tablets, capsules or any other solid dosage forms.
- the lipase solution is a homogeneous mixture which includes pharmaceutical forms referred to as water, aromatic waters, aqueous acids, solutions.
- the lipase suspension refers to a two-phase system consisting of solid lipase dispersed in a liquid.
- Example 1 Accumulated fat levels in the patient's stool during treatment with placebo or verum - Fig. 1 -
- Bacterial lipase was tested during a clinical study in cystic fibrosis patients. As shown in Figure 1 and the table below, for the indication of the fat absorption coefficient of patients on placebo and verum, there are significant differences in the amount of fat in the faeces of the patients taking Verum as well as the fat adsorption coefficient (CFA). The bacterial lipase significantly improves the breakdown of fat during digestion.
- Example 2 Activity of lipase under conditions of low pH (imitation of the pH in the stomach) - Fig. 2 -
- Bacterial lipase was dissolved and adjusted to the pH of 1.0, 2.0, 3.0, 4.0 and 5.0. Lipase activities were measured using the tributyrin test after 15, 30 min and 1, 2, 4 and 18 hours at the test pH (8.0).
- Example 3 Stability of Bacterial Lipase in Aqueous Solution - Fig. 3 -
- Bacterial Lipase was dissolved in water and incubated at 4 ° C, room temperature and 4O 0 C. The activity was measured after 1, 2, 3, 4, 5, 10 and 14 weeks. No significant loss of activity was noted during this period.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009801474407A CN102231988A (zh) | 2009-01-29 | 2009-01-29 | 细菌脂肪酶药物制剂 |
PT97763460T PT2391382E (pt) | 2009-01-29 | 2009-01-29 | Preparado farmacêutico contendo lipase de origem bacteriana |
EP09776346.0A EP2391382B1 (de) | 2009-01-29 | 2009-01-29 | Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs |
SI200930988T SI2391382T1 (sl) | 2009-01-29 | 2009-01-29 | Farmacevtski pripravek, ki vsebuje lipazo bakterijskega izvora |
JP2011546599A JP5970189B2 (ja) | 2009-01-29 | 2009-01-29 | 医薬調製物 |
EP14170910.5A EP2786761A1 (de) | 2009-01-29 | 2009-01-29 | Pharmazeutisches Präparat |
PCT/EP2009/000566 WO2010085975A1 (de) | 2009-01-29 | 2009-01-29 | Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs |
PL09776346T PL2391382T3 (pl) | 2009-01-29 | 2009-01-29 | Preparat farmaceutyczny zawierający lipazę pochodzenia bakteryjnego |
US13/146,653 US20110293590A1 (en) | 2009-01-29 | 2009-01-29 | Pharmaceutical preparation |
ES09776346.0T ES2488407T3 (es) | 2009-01-29 | 2009-01-29 | Preparación farmacéutica que contiene lipasa de origen bacteriano |
DK09776346.0T DK2391382T3 (da) | 2009-01-29 | 2009-01-29 | Farmaceutisk præparat indeholdende lipase af bakteriel oprindelse |
BRPI0922653A BRPI0922653B8 (pt) | 2009-01-29 | 2009-01-29 | uso de uma lipase bacteriana do tipo pseudomonas em solução aquosa |
HRP20140715AT HRP20140715T1 (hr) | 2009-01-29 | 2014-07-25 | Farmaceutski preparat koji sadrži lipazu bakterijskog porijekla |
CY20141100699T CY1115519T1 (el) | 2009-01-29 | 2014-09-02 | Φαρμακευτικο παρασκευασμα που περιεχει λιπαση βακτηριακης προελευσης |
US15/182,779 US10596235B2 (en) | 2009-01-29 | 2016-06-15 | Pharmaceutical preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2009/000566 WO2010085975A1 (de) | 2009-01-29 | 2009-01-29 | Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/146,653 A-371-Of-International US20110293590A1 (en) | 2009-01-29 | 2009-01-29 | Pharmaceutical preparation |
US15/182,779 Continuation US10596235B2 (en) | 2009-01-29 | 2016-06-15 | Pharmaceutical preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010085975A1 true WO2010085975A1 (de) | 2010-08-05 |
Family
ID=41091375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2009/000566 WO2010085975A1 (de) | 2009-01-29 | 2009-01-29 | Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs |
Country Status (13)
Country | Link |
---|---|
US (2) | US20110293590A1 (de) |
EP (2) | EP2786761A1 (de) |
JP (1) | JP5970189B2 (de) |
CN (1) | CN102231988A (de) |
BR (1) | BRPI0922653B8 (de) |
CY (1) | CY1115519T1 (de) |
DK (1) | DK2391382T3 (de) |
ES (1) | ES2488407T3 (de) |
HR (1) | HRP20140715T1 (de) |
PL (1) | PL2391382T3 (de) |
PT (1) | PT2391382E (de) |
SI (1) | SI2391382T1 (de) |
WO (1) | WO2010085975A1 (de) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8268305B1 (en) | 2011-09-23 | 2012-09-18 | Bio-Cat, Inc. | Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase |
WO2013146529A1 (ja) * | 2012-03-28 | 2013-10-03 | 不二製油株式会社 | ランダムエステル交換油脂の製造方法 |
US8691282B2 (en) | 2011-02-17 | 2014-04-08 | Nordmark Areneimittel GmbH & Co. KG | Method for producing pancreatin pellets |
US8999394B2 (en) | 2009-08-28 | 2015-04-07 | Thomas Moest | Pancreatine pellets and method of producing same |
US9107966B2 (en) | 2008-08-27 | 2015-08-18 | Nordmark Arzeimittel GmbH and Co, KG | Method for reducing the viral and microbial load of biological extracts containing solids |
DE102015114857A1 (de) | 2015-09-04 | 2017-03-09 | Nordmark Arzneimittel Gmbh & Co. Kg | Getränk, enthaltend eine pharmazeutische Zusammensetzung |
DE102017104501A1 (de) | 2017-03-03 | 2018-09-06 | Nordmark Arzneimittel Gmbh & Co. Kg | Pharmazeutische Zusammensetzung umfassend einen Träger und einen Überzug enthaltend wenigstens eine Lipase |
DE102017104472A1 (de) | 2017-03-03 | 2018-09-06 | Nordmark Arzneimittel Gmbh & Co. Kg | Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung |
WO2018158467A1 (de) * | 2017-03-03 | 2018-09-07 | Nordmark Arzneimittel Gmbh & Co. Kg | Wässrige lösung von burlulipase umfassend kalziumionen |
WO2018158465A1 (de) | 2017-03-03 | 2018-09-07 | Nordmark Arzneimittel Gmbh & Co. Kg | Pharmazeutische zusammensetzung umfassend pankreatin und einen lipasehaltigen überzug |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220106738A (ko) | 2019-08-30 | 2022-07-29 | 코덱시스, 인코포레이티드 | 조작된 리파제 변이체 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489530A (en) | 1991-07-01 | 1996-02-06 | Basf Aktiengesellschaft | Lipase from Pseudomonas and strain |
US20050250817A1 (en) | 2004-03-22 | 2005-11-10 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions of lipase-containing products, in particular of pancreation |
WO2006044529A1 (en) | 2004-10-14 | 2006-04-27 | Altus Pharmaceuticals Inc. | Compositions containing lipase; protease and amylase for treating pancreatic insufficiency |
WO2008127567A1 (en) | 2007-04-13 | 2008-10-23 | Beth Israel Deaconess Medical Center, Inc. | Novel nutritional food products for improved digestion and intestinal absorption |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2189948A (en) | 1938-10-31 | 1940-02-13 | Griffith Laboratories | Sterilization of pancreatin |
DE2923279B1 (de) | 1979-06-08 | 1980-11-20 | Kali Chemie Pharma Gmbh | Verfahren zur Herstellung von Pankreatin-Pellets |
US5063160A (en) * | 1989-03-16 | 1991-11-05 | Olin Corporation | Identification, characterization, and method of production of a novel microbial lipase |
JP3025528B2 (ja) | 1989-11-24 | 2000-03-27 | ビオヘミー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | パンクレアチン製剤 |
DK173590D0 (da) * | 1990-06-06 | 1990-07-19 | Novo Nordisk As | Rekombinante terapeutiske lipaser |
DE4227385A1 (de) | 1992-08-19 | 1994-02-24 | Kali Chemie Pharma Gmbh | Pankreatinmikropellets |
JPH08143469A (ja) * | 1994-11-14 | 1996-06-04 | Amano Pharmaceut Co Ltd | 膵外分泌機能不全症治療剤 |
DE19724845A1 (de) * | 1996-08-28 | 1998-03-05 | Solvay Pharm Gmbh | Verwendung von komplexen Lipiden als stabilisierende Zusätze zu pharmazeutischen Zubereitungen von Verdauungsenzymgemischen |
US6270723B1 (en) | 1998-06-15 | 2001-08-07 | Bbi Bioseq, Inc. | Rapid cryobaric sterilization and vaccine preparation |
US20010046493A1 (en) * | 2000-02-24 | 2001-11-29 | Alex Margolin | Lipase-containing composition and methods of use thereof |
BR0109918A (pt) * | 2000-04-06 | 2003-02-04 | Hannah Res Inst | Emulsões estabilizadas de proteìna |
AT502588B1 (de) * | 2002-11-26 | 2010-05-15 | Brenner Franz | Papaya-mus |
EP1486415A1 (de) | 2003-06-12 | 2004-12-15 | SSP Technology A/S | Windturbinenflügel und Verfahren zur Herstellung einer Turbinenflügelwurzel |
US6908789B1 (en) | 2003-12-15 | 2005-06-21 | Intel Corporation | Method of making a microelectronic assembly |
DE102004056340B4 (de) | 2004-11-22 | 2010-11-18 | Repower Systems Ag | Vorrichtung und Verfahren zur Montage und/oder Demontage eines Bauteils einer Windkraftanlage |
DE102005014868A1 (de) | 2005-03-30 | 2006-10-05 | Repower Systems Ag | Offshore-Windenergieanlage mit rutschfesten Füßen |
US11266607B2 (en) | 2005-08-15 | 2022-03-08 | AbbVie Pharmaceuticals GmbH | Process for the manufacture and use of pancreatin micropellet cores |
DE102006021982C5 (de) | 2006-05-10 | 2010-10-07 | Repower Systems Ag | Gestaffelt abschaltbarer Windpark |
ES2674681T3 (es) * | 2007-02-20 | 2018-07-03 | Allergan Pharmaceuticals International Limited | Composiciones estables de enzimas digestivas |
DE102007014863A1 (de) | 2007-03-26 | 2008-10-02 | Repower Systems Ag | Verfahren zum Betreiben einer Windenergieanlage |
DE102008012664A1 (de) | 2008-01-30 | 2009-08-06 | Repower Systems Ag | Windenergieanlage und ein Turm oder Turmsegment und eine Türzarge dafür |
EP2165717A1 (de) | 2008-08-27 | 2010-03-24 | Nordmark Arzneimittel GmbH & Co.KG | Verfahren zur Verringerung der viralen und mikrobiellen Belastung feststoffhaltiger biologischer Extrakte |
EP2295039B2 (de) | 2009-08-28 | 2022-10-26 | Nordmark Pharma GmbH | Verfahren zur Herstellung von Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und hiernach hergestellte Pankreatin-Pellets |
EP2489349B1 (de) | 2011-02-17 | 2014-05-28 | Nordmark Arzneimittel GmbH & Co.KG | Pankreatin-Pellets, insbesondere Pankreatin-Mikropellets, und Verfahren zu deren Herstellung |
-
2009
- 2009-01-29 SI SI200930988T patent/SI2391382T1/sl unknown
- 2009-01-29 BR BRPI0922653A patent/BRPI0922653B8/pt active IP Right Grant
- 2009-01-29 DK DK09776346.0T patent/DK2391382T3/da active
- 2009-01-29 EP EP14170910.5A patent/EP2786761A1/de not_active Withdrawn
- 2009-01-29 ES ES09776346.0T patent/ES2488407T3/es active Active
- 2009-01-29 EP EP09776346.0A patent/EP2391382B1/de active Active
- 2009-01-29 US US13/146,653 patent/US20110293590A1/en not_active Abandoned
- 2009-01-29 JP JP2011546599A patent/JP5970189B2/ja active Active
- 2009-01-29 WO PCT/EP2009/000566 patent/WO2010085975A1/de active Application Filing
- 2009-01-29 PL PL09776346T patent/PL2391382T3/pl unknown
- 2009-01-29 PT PT97763460T patent/PT2391382E/pt unknown
- 2009-01-29 CN CN2009801474407A patent/CN102231988A/zh active Pending
-
2014
- 2014-07-25 HR HRP20140715AT patent/HRP20140715T1/hr unknown
- 2014-09-02 CY CY20141100699T patent/CY1115519T1/el unknown
-
2016
- 2016-06-15 US US15/182,779 patent/US10596235B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5489530A (en) | 1991-07-01 | 1996-02-06 | Basf Aktiengesellschaft | Lipase from Pseudomonas and strain |
US5645832A (en) | 1991-07-01 | 1997-07-08 | Basf Aktiengesellschaft | Use of lipases for producing drugs |
US20050250817A1 (en) | 2004-03-22 | 2005-11-10 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions of lipase-containing products, in particular of pancreation |
WO2006044529A1 (en) | 2004-10-14 | 2006-04-27 | Altus Pharmaceuticals Inc. | Compositions containing lipase; protease and amylase for treating pancreatic insufficiency |
WO2008127567A1 (en) | 2007-04-13 | 2008-10-23 | Beth Israel Deaconess Medical Center, Inc. | Novel nutritional food products for improved digestion and intestinal absorption |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9107966B2 (en) | 2008-08-27 | 2015-08-18 | Nordmark Arzeimittel GmbH and Co, KG | Method for reducing the viral and microbial load of biological extracts containing solids |
US8999394B2 (en) | 2009-08-28 | 2015-04-07 | Thomas Moest | Pancreatine pellets and method of producing same |
US8691282B2 (en) | 2011-02-17 | 2014-04-08 | Nordmark Areneimittel GmbH & Co. KG | Method for producing pancreatin pellets |
US8268305B1 (en) | 2011-09-23 | 2012-09-18 | Bio-Cat, Inc. | Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase |
US9555083B2 (en) | 2011-09-23 | 2017-01-31 | Bio-Cat, Inc. | Methods and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase |
WO2013146529A1 (ja) * | 2012-03-28 | 2013-10-03 | 不二製油株式会社 | ランダムエステル交換油脂の製造方法 |
DE102015114857A1 (de) | 2015-09-04 | 2017-03-09 | Nordmark Arzneimittel Gmbh & Co. Kg | Getränk, enthaltend eine pharmazeutische Zusammensetzung |
DE102017104501A1 (de) | 2017-03-03 | 2018-09-06 | Nordmark Arzneimittel Gmbh & Co. Kg | Pharmazeutische Zusammensetzung umfassend einen Träger und einen Überzug enthaltend wenigstens eine Lipase |
DE102017104472A1 (de) | 2017-03-03 | 2018-09-06 | Nordmark Arzneimittel Gmbh & Co. Kg | Schmelztablette enthaltend Burlulipase und daraus hergestellte pharmazeutische Zusammensetzung |
WO2018158467A1 (de) * | 2017-03-03 | 2018-09-07 | Nordmark Arzneimittel Gmbh & Co. Kg | Wässrige lösung von burlulipase umfassend kalziumionen |
WO2018158465A1 (de) | 2017-03-03 | 2018-09-07 | Nordmark Arzneimittel Gmbh & Co. Kg | Pharmazeutische zusammensetzung umfassend pankreatin und einen lipasehaltigen überzug |
WO2018158459A1 (de) | 2017-03-03 | 2018-09-07 | Nordmark Arzneimittel Gmbh & Co. Kg | Schmelztablette enthaltend burlulipase und daraus hergestellte pharmazeutische zusammensetzung |
US11439691B2 (en) | 2017-03-03 | 2022-09-13 | Nordmark Pharma Gmbh | Aqueous solution of burlulipase comprising calciumions |
US11464834B2 (en) | 2017-03-03 | 2022-10-11 | Nordmark Pharma Gmbh | Orodispersible tablet containing burlulipase and pharmaceutical composition produced therefrom |
Also Published As
Publication number | Publication date |
---|---|
PT2391382E (pt) | 2014-08-22 |
CY1115519T1 (el) | 2017-01-04 |
EP2391382A1 (de) | 2011-12-07 |
ES2488407T3 (es) | 2014-08-27 |
JP5970189B2 (ja) | 2016-08-17 |
SI2391382T1 (sl) | 2014-10-30 |
EP2391382B1 (de) | 2014-06-04 |
HRP20140715T1 (hr) | 2014-09-26 |
PL2391382T3 (pl) | 2014-11-28 |
CN102231988A (zh) | 2011-11-02 |
DK2391382T3 (da) | 2014-08-25 |
US20160287679A1 (en) | 2016-10-06 |
EP2786761A1 (de) | 2014-10-08 |
JP2012516289A (ja) | 2012-07-19 |
US20110293590A1 (en) | 2011-12-01 |
BRPI0922653B1 (pt) | 2021-04-13 |
BRPI0922653A2 (pt) | 2016-01-05 |
BRPI0922653B8 (pt) | 2021-05-25 |
US10596235B2 (en) | 2020-03-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2391382B1 (de) | Pharmazeutisches präparat enthaltend lipase bakteriellen ursprungs | |
EP0918458B1 (de) | Antimikrobielle behandlung von herpes simplex viren und anderer infektioser erkrankungen | |
DE69634248T2 (de) | Zusammensetzungen zur verbesserung der verdaulichkeit und ausnutzung von nähestoffen | |
EP1381386A2 (de) | Gemische von enzymen aus pilzen und deren verwendung zur behandlung der maldigestion | |
DE102009006594A1 (de) | Pharmazeutisches Präparat | |
EP1330262B1 (de) | Verwendung von aus ciliaten gewonnenen enzymen als verdauungsfördernde arzneimittel | |
EP3525769B1 (de) | Schmelztablette enthaltend burlulipase und daraus hergestellte pharmazeutische zusammensetzung | |
DE60124516T2 (de) | Kombination des lezithins mit ascorbinsäure | |
DE102015114857A1 (de) | Getränk, enthaltend eine pharmazeutische Zusammensetzung | |
WO2019043064A1 (de) | Zusammensetzung zur topischen behandlung von nicht-mikroorganismus-verursachten entzündlichen haut- und schleimhauterkrankungen | |
EP3589275A1 (de) | Pharmazeutische zusammensetzung umfassend pankreatin und einen lipasehaltigen überzug | |
US11986485B1 (en) | Compositions and methods for treating epilepsy | |
US11931369B1 (en) | Compositions and methods for treating epilepsy | |
WO2002072112A1 (de) | Verwendung von selenit- oder selenathaltigen präparaten zur behandlung von wunden | |
DE1667891A1 (de) | Neue therapeutische Zusammensetzungen mit analgetischer Wirksamkeit | |
DE4236064C2 (de) | Selektiv-toxisches Mittel und seine Verwendung | |
EP1891940B1 (de) | Intrasynoviale Stanozololformulierungen | |
JPH0952844A (ja) | 酵素含有内服液剤 | |
DE102015114862A1 (de) | Pharmazeutische Zusammensetzung, enthaltend eine bakterielle Lipase | |
DE10144711A1 (de) | Neue Gemische mikrobieller Enzyme | |
DE3341760A1 (de) | Arzneimittel mit einer phagocyten-kontrollwirkung | |
JPH0952845A (ja) | 保存安定性の高められた酵素含有内服液剤 | |
JPH11322623A (ja) | ヘルペスシンプレックスウイルスおよび他の感染病のための抗菌治療 | |
WO2005007177A1 (de) | Pharmazeutischer wirkstoff gegen magengeschwüre | |
CN106139132A (zh) | 细菌脂肪酶药物制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980147440.7 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09776346 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011546599 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009776346 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13146653 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: PI0922653 Country of ref document: BR Kind code of ref document: A2 Effective date: 20110615 |